17 results on '"Zeidler, Claudia"'
Search Results
2. Pruritus im Alter: Jeder Fünfte ist betroffen
- Author
-
Zeidler, Claudia, Raap, Ulrike, and Ständer, Sonja
- Published
- 2015
- Full Text
- View/download PDF
3. Healthcare Utilization and Treatment Patterns in Patients with Chronic Prurigo and Chronic Pruritus in Germany.
- Author
-
Ständer, Sonja, Garbe, Claudia, Hagenström, Kristina, Petersen, Jana, Zeidler, Claudia, and Augustin, Matthias
- Subjects
PRURIGO ,ITCHING ,DRUG prescribing ,MEDICAL care ,DRUGS ,DERMATOLOGISTS - Abstract
Background: To date, there have been no large studies describing real-world treatment of chronic prurigo (CPG) and pruritus (CPR) in Germany. Objective: To determine the healthcare utilization, treatment patterns, and costs associated with CPG and CPR in Germany. Methods: Retrospective analysis using anonymized claims data (German DAK-Gesundheit), based on a 40% sample of all insured adults of the DAK-Gesundheit on December 31, 2010 (N = 2,006,003). Results: Patients with CPR (prevalence 2.2%) most commonly visited general medicine/general practitioners (GPs, 80.1%), followed by gynecologists (66.1%) and dermatologists (51.1%). Patients with CPG (prevalence 0.2%) most commonly visited dermatologists (85.7%), GPs (78.1%), and ophthalmologists (47.2%). Of adult patients, 44% received at least one drug prescription. Two thirds of patients with a drug prescription received ≥1 topical drug (66.2%), and 54.3% ≥1 systemic drug (total costs of approximately EUR 550,000 and 2,500,000, respectively). Of patients with CPG, 33.8% received ≥1 systemic and 45.1% ≥1 topical drug prescription (costs of approximately EUR 360,000 vs. 105,000). Of patients with CPR, 23.5% received ≥1 systemic and 28.6% ≥1 topical drug prescription (costs of approximately EUR 2,000,000 vs. 500,000). Of patients with CPG, 5.8% received ≥1 phototherapy application vs. 1.2% of patients with CPR. Conclusions: These findings reflect the reality of care and can form a basis for the identification of overuse, underuse, and misuse in order to design CPG and CPR healthcare more effectively and efficiently. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Pruritus in Autoimmune and Inflammatory Dermatoses
- Author
-
Zeidler, Claudia, Pereira, Manuel Pedro, Huet, Flavien, Misery, Laurent, Steinbrink, Kerstin, Ständer, Sonja, and Universitäts- und Landesbibliothek Münster
- Subjects
bullous pemphigoid ,atopic dermatitis ,integumentary system ,Mini Review ,substance P ,Pruritus ,Immunology ,Dermatitis ,psoriasis ,Skin Diseases ,Autoimmune Diseases ,body regions ,Medicine and health ,Humans ,itch ,ddc:610 ,skin and connective tissue diseases ,pruritus ,IL31 - Abstract
Pruritus in autoimmune and inflammatory dermatoses is a common symptom that can be severe and affect the quality of life of patients. In some diseases, pruritus is related to disorders activity and severity or may occur independent of the disease. Despite the high prevalence, the symptom is still underrated and there are only a few trials investigating the efficacy of drugs for disease-specific pruritus. In this review, the characteristics and possible pathomechanisms of pruritus in various dermatoses like autoimmune bullous diseases, connective tissue diseases as well as autoimmune-associated dermatoses (atopic dermatitis, psoriasis vulgaris) is illustrated. Additionally, studies analyzing the antipruritic treatment are discussed. Summarizing, the prevalence of pruritus in these diseases demonstrates the importance for symptom recognition and the need for an efficient antipruritic therapy.
- Published
- 2020
5. Introduction of a Specific Dermatological Rehabilitation Programme for Patients with Chronic Pruritus: A Pilot Study.
- Author
-
VON MARTIAL, Sophia, KOK, Lisa, GRÜNDEL, Sonja, AUGUSTIN, Matthias, BLOME, Christine, ZEIDLER, Claudia, STEINBRINK, Kerstin, STÄNDER, Sonja, and TSIANAKAS, Athanasios
- Subjects
TREATMENT programs ,MEDICAL care ,ITCHING ,MEDICAL rehabilitation ,PATIENT satisfaction ,PILOT projects ,NEUROPSYCHOLOGICAL rehabilitation - Abstract
Chronic pruritus is a common symptom, associated with several severe medical conditions, great psychological burden, and reduced quality of life. It also poses socio-economic challenges concerning patients' work loss and healthcare costs. In Germany, medical rehabilitation programmes represent an integral part of the medical care of patients with chronic inflammatory skin diseases. However, such programmes play only a rudimentary role in the treatment of other dermatological diseases, such as dermatological oncology, genetic skin diseases, and chronic pruritus. Therefore, a specific antipruritic dermatological rehabilitation programme was developed in cooperation between the Department of Dermatology of the Medical Rehabilitation Center Bad Bentheim and the Center for Chronic Pruritus of the University Hospital of Muenster, Germany. This prospective study compared short-term patient-reported outcomes (n = 121) at the beginning and end of the rehabilitation programme. The majority of subjects had chronic pruritus on primary diseased, inflamed skin. Significant improvements in pruritus intensity (p ≤ 0.001), quality of life (p ≤ 0.001), anxiety symptoms (p ≤ 0.001) and depression (p ≤ 0.001), as well as an overall patientrelevant benefit (Patient Benefit Index 2.6 ± 1.06) and treatment-related patients' satisfaction, were shown. This suggests that implementation of this standardized rehabilitation programme for treatment of patients with chronic pruritus was successful. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Hand Pruritus: Clinical Profile, Functional Impairment and Diseaserelated Burden in a Prospective Cohort Study of 395 Patients.
- Author
-
NAU, Teresa Gabriele, RAU, Viola, ZEIDLER, Claudia, STÄNDER, Sonja, and PEREIRA, Manuel P.
- Subjects
QUALITY of life ,COHORT analysis ,LONGITUDINAL method ,ACTIVITIES of daily living ,SYMPTOMS ,ITCHING - Abstract
Human hands are complex structures essential for a variety of functions in everyday life. This study prospectively investigated the clinical features of hand pruritus and the resulting functional impairment and disease-related burden in 395 patients with chronic pruritus (210 females, median age 59 years). Moderate to very severe hand pruritus was reported by 91.2% of patients, while 79% perceived additional sensory symptoms, such as burning, pain or tingling. A long duration of pruritus occurred in most cases (> 6 months: 71.4%). A considerable proportion of patients showed moderate to severe impairment in the use of their hands (40.2%), performance of daily activities (65.0%) and quality of life (45.2%). Disease severity and burden is particularly high when both the palms and the backs of the hands are affected, and when pain is present simultaneously. Pruritus located on the hands is impairing and burdensome due to the functional relevance of the hands in everyday life. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden.
- Author
-
PEREIRA, Manuel P., FARCAS, Alexandra, ZEIDLER, Claudia, and STÄNDER, Sonja
- Subjects
ITCHING ,QUALITY of life ,VISUAL analog scale - Abstract
Chronic pruritus of unknown origin is established when no underlying origin for pruritus can be determined. This retrospective cohort study aimed to determine the clinical profile and disease-related burden of chronic pruritus of unknown origin. A total of 263 patients (female/male: 154/109, median age 55 years) were included. Moderate to severe itch intensities were recorded (median average itch: 5.5/10, n = 200; median worst itch: 7.5/10, n = 199). In most cases pruritus lasted longer than 1 year (77.6%), occurred daily (68.2%), occurred in attacks (72.8%), and was often accompanied by dysaesthesias, such as burning, tingling and stinging. Quality of life was moderately impaired, while 22.2% and 12.4% of patients showed pathological anxiety and depression scores. Scratch lesions were associated with higher intensities of itch and greater impairment of quality of life, while women were more burdened by the disease than men. Chronic pruritus of unknown origin may occur at any age and the majority of patients endure severe itch with substantial disease-related burden. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Challenges in Clinical Research and Care in Pruritus.
- Author
-
PEREIRA, Manuel P., ZEIDLER, Claudia, STORCK, Michael, AGELOPOULOS, Konstantin, PHILIPP-DORMSTON, Wolfgang G., ZINK, Alexander, and STÄNDER, Sonja
- Subjects
- *
ITCHING , *TRANSLATIONAL research , *PATHOLOGICAL physiology - Abstract
Chronic pruritus is a frequent global condition. The pathophysiology, underlying aetiology, clinical manifestation, associated burden and response to therapy of chronic pruritus varies from patient to patient, making clinical research and management of this condition challenging. There are still several unmet needs, such as the need to standardize translational research protocols, diagnostic and therapeutic procedures and to enhance the knowledge of the humanistic and economic burden associated with chronic pruritus. Basic and clinical research is of the utmost importance to target these matters. Clinical research has the potential to identify new relevant mechanisms in affected patients, which may lead to identification of novel therapy targets. This article discusses in depth current shortcomings in the daily care of patients with chronic pruritus and the challenges clinical researchers and physicians treating chronic pruritus face in addressing these matters. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Pruritus in Autoimmune and Inflammatory Dermatoses.
- Author
-
Zeidler, Claudia, Pereira, Manuel Pedro, Huet, Flavien, Misery, Laurent, Steinbrink, Kerstin, and Ständer, Sonja
- Subjects
ITCHING ,SKIN diseases ,CONNECTIVE tissue diseases ,ATOPIC dermatitis ,DRUG efficacy ,BULLOUS pemphigoid - Abstract
Pruritus in autoimmune and inflammatory dermatoses is a common symptom that can be severe and affect the quality of life of patients. In some diseases, pruritus is related to disorders activity and severity or may occur independent of the disease. Despite the high prevalence, the symptom is still underrated and there are only a few trials investigating the efficacy of drugs for disease-specific pruritus. In this review, the characteristics and possible pathomechanisms of pruritus in various dermatoses like autoimmune bullous diseases, connective tissue diseases as well as autoimmune-associated dermatoses (atopic dermatitis, psoriasis vulgaris) is illustrated. Additionally, studies analyzing the antipruritic treatment are discussed. Summarizing, the prevalence of pruritus in these diseases demonstrates the importance for symptom recognition and the need for an efficient antipruritic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Validation of a Comprehensive Set of Pruritus Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS.
- Author
-
VERWEYEN, Emely, STÄNDER, Sonja, KREITZ, Kiana, HÖBEN, Inga, OSADA, Nani, GERNART, Marvin, RIEPE, Claudia, PEREIRA, Manuel, BLOME, Christine, AUGUSTIN, Matthias, and ZEIDLER, Claudia
- Subjects
ITCHING ,INTRACLASS correlation ,RAPID tooling ,STATISTICAL reliability ,TEST validity - Abstract
Few studies have validated standard measurement instruments for evaluation of chronic pruritus. The Chronic Pruritus Tools Questionnaire PRURITOOLS assembles a set of instruments for the assessment of pruritus, such as the visual analogue scale (horizontal 100-mm line), numerical rating scale (0-10), verbal rating scale, and information on pruritus quality and improvement during therapy. This study, with 40 subjects, analysed PRURITOOLS regarding convergent validity and test-retest reliability (60 min), followed by a feasibility questionnaire. Test-retest reliability for PRURITOOLS items was excellent (intraclass correlation coefficient 0.84-1). Strong to very strong correlations between the pruritus intensity scales indicated convergent validity. The feasibility questionnaire showed an overall acceptance of PRURITOOLS, and the majority of subjects (82.5%) considered it an appropriate questionnaire to measure pruritus. In conclusion, PRURITOOLS offers validated tools for rapid pruritus assessment in routine care or endpoints of clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
- Author
-
TSIANAKAS, Athanasios, ZEIDLER, Claudia, RIEPE, Claudia, BOROWSKI, Matthias, FORNER, Caroline, GERSS, Joachim, METZ, Martin, STAUBACH, Petra, RAAP, Ulrike, KAATZ, Martin, URBAN, Marc, LUGER, Thomas A., and STÄNDER, Sonja
- Subjects
- *
SUBSTANCE P receptors , *ITCHING , *SUBSTANCE P - Abstract
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks. Following a 2-week wash-out phase, the patients were crossedover to receive the other treatment for 4 weeks. Primary efficacy criterion was the intra-individual difference between mean itch intensity (visual analogue scale) at baseline compared with the end of treatment period. Prurigo lesions, pruritus course, quality of life, patient benefits, and safety were secondary parameters. No significant differences were found between aprepitant treatment and placebo for any of the parameters investigated. Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Exploratory Study of Intracutaneous Histamine Stimulation in Patient Populations with Chronic Pruritus.
- Author
-
TSIANAKAS, Athanasios, NIPPE, Nadine, HAMPER, Christina Maria, CORDES, Anna Friederike, ZEIDLER, Claudia, SCHMELZ, Martin, and STÄNDER, Sonja
- Subjects
ITCHING ,HISTAMINE - Abstract
Chronic pruritus can be a diagnostic sign of an underlying disease. In the intracutaneous histamine test, histamine (one of the best-known inducers of pruritus) may cause different reaction patterns depending on the underlying disease. The aim of this study was to determine if an intracutaneous injection of histamine can differentiate between the causes of chronic pruritus and thus be used as a diagnostic test in chronic pruritus of unknown aetiology. A total of 140 subjects with chronic pruritus with various dermatological, systemic or neurological diseases were included. The intracutaneous histamine test was performed once on each subject. Erythema, wheal and pruritus intensity were measured and analysed. Significantly greater wheal size was observed in patients with systemic or multifactorial causes. In general, there was a significant correlation between age and wheal size. Also, noticeable differences were found between males and females regarding pruritus and wheal size. In summary, the exact type of chronic pruritus could not be clearly determined based on the results of the intracutaneous histamine test. However, the results provide valuable insights into specific reaction patterns to experimental histamine-induced itch, e.g. sex-specific differences in the neurophysiology of pruritus, which should be considered in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Usability of Validated Sleep-assessment Questionnaires in Patients with Chronic Pruritus: An Interview-based Study.
- Author
-
Suilmann, Theresa, Zeidler, Claudia, Osada, Nani, Riepe, Claudia, and Ständer, Sonja
- Subjects
- *
ITCHING , *CLINICAL trials , *PRURIGO , *QUESTIONNAIRES , *INSOMNIA , *DIAGNOSIS - Abstract
Impaired sleep due to nocturnal pruritus is a common symptom in patients with chronic pruritus. How ever, there is no standardized, simplified instrument for assessing sleep-related problems in patients with chronic pruritus. After a literature search, we conducted 50 interviews with patients with chronic pruritus and tested 12 items most frequently used in routine sleep questionnaires. Afterwards, 2 sleep assessment questionnaires (Pittsburgh Sleep Quality Index; Regensburg Insomnia Scale) were selected for use in 88 patients with chronic pruritus with sleep impairment due to pruritus. They were completed twice; once before optimizing their individual pruritus therapy and once again after 4 weeks. During the latter survey, 21 patients reported that pruritus no longer negatively affected their sleep. These patients also achieved a significant improvement in their sleeping behaviour in the Regensburg Insomnia Scale. Therefore, the Regensburg Insomnia Scale appears to be well-suited to assessing sleep impairment in patients with chronic pruritus. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Chronic Prurigo of Nodular Type: A Review.
- Author
-
ZEIDLER, Claudia, TSIANAKAS, Athanasios, PEREIRA, Manuel, STÄNDER, Hartmut, YOSIPOVITCH, Gil, and STÄNDER, Sonja
- Subjects
- *
PRURIGO , *ITCHING , *NODULAR disease , *STEROIDS , *CAPSAICIN , *THERAPEUTICS - Abstract
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules. PN evolves along with chronic pruritus in the context of diverse dermatological, systemic, neurological or psychiatric conditions. Permanent scratching is possibly a major trigger of PN, although its exact pathophysiology remains unclear. Current state-of-the-art therapy for PN consists of topical steroids, capsaicin, calcineurin inhibitors, ultraviolet (UV) therapy, systemic administration of gabapentinoids, µ-opioid receptor antagonists, antidepressants or immunosuppressants. Novel treatment concepts, such as inhibitors of neurokinin-1, opioid and interleukin-31 receptors, have been developed and are currently being clinically tested. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. ItchApp©: An App-based eDiary for Assessment of Chronic Pruritus in Clinical Trials.
- Author
-
GERNART, Marvin, TSIANAKAS, Athanasios, ZEIDLER, Claudia, RIEPE, Claudia, OSADA, Nani, PIHAN, David, and STÄNDER, Sonja
- Subjects
ITCHING ,CLINICAL trials ,ELECTRONIC health records ,RANDOMIZED controlled trials ,DIAGNOSIS - Abstract
Performing a reliable assessment of chronic pruritus remains a challenge. Electronic diaries are often used, but many of the scales have not been validated. ItchApp
© was developed for Android smartphones in order to address this lack. A total of 40 subjects with chronic pruritus completed questionnaires both on paper and with ItchApp© (verbal rating scale, numerical rating scale, dynamic pruritus score) in order to validate the software application. Strong correlations were found for test–retest reliability (intraclass correlation coefficient: 0.865-0.977) and convergent validity (Spearman's r: 0.442-0.924). A feasibility questionnaire for ItchApp© revealed a high level of user friendliness and compliance. This was confirmed in a randomized controlled trial with 68 subjects, for which the clinically important difference in the numerical rating scale values for ItchApp© was calculated (2.61 points). In summary, ItchApp© is a recently developed eDiary that can provide experts with a reliable evaluation of patients with chronic pruritus. It will be made available for future clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus.
- Author
-
STÄNDER, Sonja, BLOME, Christine, ANASTASIADOU, Zografia, ZEIDLER, Claudia, JUNG, Katharina Anna, TSIANAKAS, Athanasios, Gitta NEUFANG, Gitta, and AUGUSTIN, Matthias
- Subjects
TEST validity ,TEST reliability ,ITCHING ,VISUAL analog scale ,QUALITY of life - Abstract
Currently valid itch intensity scales, such as the visual analogue scale (VAS), are indispensable, but they can be influenced by the patient's overall health status. The aim of this study was to evaluate the reliability and validity of the Dynamic Pruritus Score (DPS), a new instrument comparing reduction in current pruritus with a defined earlier time-point. Eighty-one randomly selected adults (50 females, mean age 53.9 years) recorded their pruritus at visit 1 and repeatedly at visit 2 on the DPS, VAS, numerical rating scale, and on health status questionnaires (EuroQol; EQ-5D), skin-related quality of life (Dermatology Life Quality Index; DLQI), anxiety and depression (Hospital Anxiety and Depression Scale; HADS) and patient benefit (Patient Benefit Index; PBI). Intraclass correlation showed high reliability for both DPS and VAS (r > 0.9, p < 0.001), while the DPS has shown higher concurrent validity (r
DPS to PBI = 0.570; p < 0.001). The DPS can then be considered an alternative instrument to the VAS for assessment of pruritus in adults. Further research is needed to confirm these results with a more representative sample size. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability.
- Author
-
STÄNDER, Sonja, METZ, Martin, RAMOS F., Mac H., MAURER, Marcus, SCHOEPKE, Nicole, TSIANAKAS, Athanasios, ZEIDLER, Claudia, and LUGER, Thomas A.
- Subjects
ANTIFUNGAL agents ,CLINICAL trials ,ITCHING ,ATOPIC dermatitis ,INSOMNIA - Abstract
This study was a prospective, parallel-group, randomized, double-blind, vehicle-controlled, multi-centre clinical trial to compare the efficacy of topical sertaconazole 2% cream with vehicle in reducing chronic pruritus in subjects with atopic dermatitis, and to assess its safety and local tolerability. A total of 70 subjects applied either of the 2 treatments twice daily for a period of 4 weeks on affected, itchy skin areas. Treatment efficacy was evaluated primarily considering the item itch intensity on a 5-point verbal rating scale. Insomnia, state of atopic dermatitis (Scoring Atopic Dermatitis; SCORAD), quality of life and therapy benefit were also assessed. No significant difference between active treatment and vehicle was found at any of the time-points for any of the investigated parameters. Under the experimental conditions of the study, sertaconazole 2% cream did not exert anti-pruritic effects that were better than vehicle in subjects with atopic dermatitis who had chronic pruritus. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.